ClinicalTrials.gov
public full text
Public Domain
PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)
The aim of this study is to evaluate the efficacy and safety of PARP Inhibition and programmed cell death protein-1 (PD-1) blockade immunotherapy with concurrent stereotactic body radiotherapy (SBRT) for metastatic or advanced bone and soft tissue sarcoma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer#1146223
- ARQ761 + PARP Inhibitor in Refractory Solid Tumors#1244530
- Optimization of Radiotherapy in Treatment of Painful Bone Metastasis#855375
- Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients#903232
- Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors#1029981
Record · ID 1294511
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive